We further showed -GST predicts stage 2 and 3 AKI at 3 hrs post surgery (AUC = 0.78)
Global burden of 369 diseases and injuries in 204 countries and territories, 19902019: a systematic analysis for the Global Burden of Disease Study 2019
A semaglutida, como um agonista do receptor do GLP-1, demonstra potencial na melhora do controle glicmico, na reduo de eventos cardiovasculares e na preservao das clulas beta do pncreas, oferecendo uma abordagem inovadora e promissora
Each works in a different way and may be affected differently by medications like tirzepatide
doi: 10.1242/jcs.248864 157 OlonaAMukhopadhyaySHateleyCMartinezFOGordonSBehmoarasJ
One of the things that I always have to remember as a fat patient is that pharmaceutical companies have a fiduciary duty to their shareholders, not to me as a patient (and there are plenty of examples of pharmaceutical companies making the decision to harm patients based on their assessment that the penalties/lawsuits will be less than the profits.) And many healthcare providers (including and especially those who work in ob*sity medicine) firmly believe that its worth risking my life and quality of life in any and all efforts to make me even a little bit thinner